Natixis’s Arena Pharmaceuticals Inc ARNA Stock Holding History

Natixis’s Portfolio ARNA Stock Details ARNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-230,000	Closed	-$21.4M	–	1383
2021 Q4	$21.4M	Buy	+230,000	New	+$15.2M	0.07%	222
2014 Q4	–	Sell	-5,543	Closed	-$232K	–	442
2014 Q3	$232K	Buy	+5,543	New	+$247K	﹤0.01%	377
2014 Q2	–	Sell	-2,720	Closed	-$171K	–	544
2014 Q1	$171K	Buy	2,720 +630	+30%	+$41.8K	﹤0.01%	439
2013 Q4	$122K	Buy	+2,090	New	+$109K	﹤0.01%	489

Natixis's ARNA Position: Q1 2022 in Review

Natixis sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 230,000 shares — an estimated $21.4M sold.

Natixis first reported a position in ARNA in Q4 2013 and held it in 4 quarters. The position peaked at $21.4M in Q4 2021. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.

Natixis reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
Natixis sold 230,000 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $21.4M.
Natixis first reported a position in Arena Pharmaceuticals Inc in Q4 2013 and held it in 4 quarters.
Natixis's Arena Pharmaceuticals Inc position peaked at $21.4M in Q4 2021.
1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.

Based on Natixis's 13F filing for Q1 2022, filed 13 May 2022.